{
    "clinical_study": {
        "@rank": "144681", 
        "arm_group": [
            {
                "arm_group_label": "Cohort A", 
                "arm_group_type": "Experimental", 
                "description": "Each subject will receive a single administration of either BL-7010 (at different amounts) or matching Placebo on 3 treatment occasions in a randomized double-blind fashion"
            }, 
            {
                "arm_group_label": "Cohort B", 
                "arm_group_type": "Experimental", 
                "description": "Each subject will receive a single administration of either BL-7010 (at different amounts) or matching Placebo on 3 treatment occasions in a randomized double-blind fashion"
            }, 
            {
                "arm_group_label": "Cohort C", 
                "arm_group_type": "Experimental", 
                "description": "Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from Cohorts A and B) in a randomized double-blind fashion"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety of different amounts of BL-7010 in\n      single oral administration and in repeated oral administration to well-controlled celiac\n      patients. Another purpose is to evaluate if BL-7010 is absorbed by the body or not."
        }, 
        "brief_title": "Safety and Systemic Exposure Study of BL-7010 in Well-Controlled Celiac Patients.", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Celiac Disease", 
        "condition_browse": {
            "mesh_term": "Celiac Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females aged 18-75 years who have signed an informed consent form\n\n          -  Body mass index (BMI) between 18.5-29.9, inclusive\n\n          -  Documented history of biopsy-proven celiac disease.\n\n          -  Adherence to a gluten-free diet for the last 6 months prior to randomization\n\n          -  TG2 and EMA antibody (IgA) negative\n\n          -  Women of childbearing potential and all men must agree to use an approved form of\n             contraception\n\n          -  Ability and willingness to understand and comply with study procedures and to give\n             written informed consent prior to enrollment.\n\n        Exclusion Criteria:\n\n          -  IgA deficiency.\n\n          -  History of IgE-mediated reactions to gluten.\n\n          -  Other food sensitivities or allergies.\n\n          -  Use of oral steroids, biologics, immunosuppressants or non-steroidal\n             anti-inflammatory drugs 6 months prior to entry (screening).\n\n          -  Female subjects who are pregnant or breastfeeding.\n\n          -  Clinically significant, concomitant gastrointestinal disease.\n\n          -  Have clinically significant current or historical medical problems such as diabetes\n             mellitus, clinically significant cardiac arrhythmias, arteriosclerotic heart disease,\n             renal insufficiency or failure, autoimmune disease, history of malignant melanoma or\n             history of cancer (excluding basal cell carcinoma) within the past 5 years prior to\n             screening.\n\n          -  Subjects receiving drugs or oral devices that, in the opinion of the Investigator,\n             possible ineffective treatment with these drugs/oral devices for a duration of two\n             weeks will put the subject at a medical risk\n\n          -  Uncontrolled complications of celiac disease.\n\n          -  Any other condition that in the opinion of the Investigator will place the subject at\n             risk or prevent protocol compliance."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01990885", 
            "org_study_id": "BL-7010.01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort A", 
                    "Cohort B", 
                    "Cohort C"
                ], 
                "intervention_name": "BL-7010", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": [
                    "Cohort A", 
                    "Cohort B", 
                    "Cohort C"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 11, 2013", 
        "location": {
            "contact": {
                "email": "tiina.karja-lahdensuu@finnmedi.com", 
                "last_name": "Tiina K\u00e4rj\u00e4-Lahdensuu", 
                "phone": "+358 400 678 332"
            }, 
            "facility": {
                "address": {
                    "city": "Tampere", 
                    "country": "Finland"
                }, 
                "name": "FinnMedi Clinical Trial Center"
            }, 
            "investigator": {
                "last_name": "Marja-Leena L\u00e4hdeaho, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Finland"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Two-Part, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Systemic Exposure of Single Escalating Administrations and Repeated Administration of BL-7010 in Well-Controlled Celiac Patients", 
        "overall_official": {
            "affiliation": "University of Tampere", 
            "last_name": "Markku M\u00e4ki, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Finland: Valvira - National Supervisory Authority for Welfare and Health"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "For Part 1 subjects will be followed for up to 7 weeks from time of first administration. For Part 2 subjects will be followed for up to  4 weeks from time of first administration"
            }, 
            {
                "measure": "Significant change from baseline in vital signs and 12-lead ECG parameters", 
                "safety_issue": "Yes", 
                "time_frame": "For Part 1 subjects will be followed for up to 7 weeks from time of first administration. For Part 2 subjects will be followed for up to  4 weeks from time of first administration"
            }, 
            {
                "measure": "Significant change from baseline in laboratory safety parameters", 
                "safety_issue": "Yes", 
                "time_frame": "For Part 1 subjects will be followed for up to 7 weeks from time of first administration. For Part 2 subjects will be followed for up to  4 weeks from time of first administration"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01990885"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Plasma levels of BL-7010", 
            "safety_issue": "No", 
            "time_frame": "Over a 24 hour peiord"
        }, 
        "source": "BioLineRx, Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BioLineRx, Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}